Elevance Health Earnings Call Transcripts
Fiscal Year 2026
-
Second quarter results exceeded expectations, prompting a raise in 2026 EPS guidance to at least $27 and reaffirming confidence in at least 12% EPS growth for 2027. Medicaid remains challenging but manageable, with targeted market exits and prudent margin outlook, while Medicare Advantage, Commercial, and Carelon segments show strong performance and growth potential.
-
Progress with CMS on Medicare Advantage sanctions is nearly complete, with no expected impact on enrollment or margins. Utilization trends support earnings guidance, while Medicaid margins are set to improve after a 2026 trough. Growth is driven by disciplined pricing, Carelon integration, and technology investments.
-
The meeting covered strong financial growth, board updates, and strategic initiatives in efficiency, digital transformation, and value-based care. All board proposals passed, while a shareholder proposal on political contributions failed.
-
Q1 results exceeded expectations with strong EPS and revenue growth, driven by ACA seasonality, cost management, and non-recurring investment income. Full-year EPS guidance was raised, and strategic investments in AI and Carelon are supporting operational improvements and long-term growth.
-
CMS sanctions relate to historical risk adjustment practices, with no impact on current operations or 2026 financial objectives. Medicaid and ACA trends are favorable, and strategic investments in AI and digital capabilities are expected to drive efficiency and growth.
Fiscal Year 2025
-
2026 is set as a year of execution and repositioning, with disciplined pricing, targeted investments, and margin stabilization across all segments. Guidance reflects a trough in Medicaid, deliberate Medicare and ACA actions, and confidence in returning to 12%+ EPS growth in 2027.
-
Q3 results met expectations with strong revenue growth and disciplined cost management. 2025 adjusted EPS is reaffirmed at ~$30, with Medicaid margins expected to trough in 2026 before improving in 2027. Strategic investments in technology and Carelon are prioritized for long-term growth.
-
Q2 results met expectations, but full-year 2025 adjusted EPS guidance was revised down to ~$30 due to persistent elevated medical cost trends in ACA and slower Medicaid rate alignment. Carelon drove strong growth, while strategic investments and cost controls aim to stabilize margins and support long-term growth.
-
The meeting covered director elections, executive compensation, and auditor ratification, with all board proposals passing and a shareholder proposal on diversity reporting failing. Financial results showed revenue and dividend growth, while strategic initiatives focused on value-based care and digital innovation.
-
Q1 2025 results met expectations with strong EPS growth, revenue up 15%, and robust performance across Medicare, Medicaid, and Carelon segments. Guidance for the year is reaffirmed, with Medicaid margin recovery expected in H2 and continued disciplined capital deployment.
-
2025 Medicare Advantage membership guidance is reaffirmed, with stable margins expected despite cost pressures. Medicaid and commercial businesses are performing in line with expectations, while specialty pharmacy trends remain elevated. The CareBridge acquisition expands home-based care capabilities.
Fiscal Year 2024
-
Fourth quarter and full-year results met expectations, with revenue up 3% and strong performance in commercial and Carelon segments. Medicaid cost trends remain elevated but stable, while Medicare Advantage is expected to grow 7%-9% in 2025. 2025 guidance includes adjusted EPS of $34.15-$34.85 and continued capital returns.
-
Investments in AI and digital capabilities, along with strategic M&A, are expected to drive long-term growth. Medicaid and Medicare Advantage margins will remain pressured in 2025, while commercial and ACA segments show strong performance. Carelon's acquisitions and partnerships are expanding capabilities and market reach.
-
Q3 results missed expectations due to elevated Medicaid costs, prompting a reduced full-year EPS outlook. Commercial and Medicare segments remain strong, while Medicaid faces time-bound margin pressure from rate-acuity mismatches. Strategic investments and acquisitions support long-term growth.
-
Q2 adjusted EPS grew 12% year-over-year to $10.12, with full-year guidance reaffirmed. Medicaid and Medicare segments face margin pressure from higher acuity and utilization, but commercial and Carelon businesses are driving growth. Significant investments and acquisitions position the company for long-term expansion.
-
Guidance was reaffirmed with stable trends across all business lines. Strategic partnerships and acquisitions are driving scalable, value-based care and specialty services, while Medicare and commercial businesses focus on disciplined margin improvement and growth. Exchange business continues to expand with healthy margins.